ESR1 and breast cancer: Recently, the ISPY-2 trial revealed that the combination of chemotherapy and pembrolizumab yielded a twofold increase in the pCR rate compared with chemotherapy alone in the ER+ subgroup (28% versus 14%) (78), indicating that the combination of chemotherapy and immune checkpoint inhibitors produces a synergistic antitumor effect in ER+ BC.